In July 2021, we entered into an agreement whereby we obtained an 80.2% interest in DomaniRx, LLC (“DomaniRx”), a variable interest entity under GAAP. We have the power to direct the majority of the activities of DomaniRx that most significantly impact its economic performance, the obligation to absorb losses and the right to receive benefits from DomaniRx. Accordingly, we determined that we are the primary beneficiary of DomaniRx and consolidate its results.

The carrying value of the assets and liabilities associated with DomaniRx included in our condensed consolidated balance sheet at March 31, 2025 and December 31, 2024, which are limited for use in its operations and do not have recourse against our general credit or our senior secured credit facilities, are as follows:


	March 31,		December 31,
	2025		2024
Assets:
Cash and cash equivalents	$	152.0	$	155.2
Prepaid expenses and other current assets		0.9		0.9
Intangible assets		222.3		217.6
Other assets		1.6		2.4
Liabilities:
Other liabilities		0.9		1.1